← Search & browse all drugs

broxyquinoline

A07AX01

Forms & Strengths

Oral tablets: 200 mg
Combination formulations with brobenzoxaldine exist in certain regions

Adult Dosing

Acute infectious diarrhea: 200 mg to 400 mg orally 3 times daily
Duration of treatment typically limited to 5 to 7 days

Pediatric Dosing

Safety and efficacy in pediatric patients not well established
Use in children generally discouraged or strictly weight-based under specialist guidance where approved

Indications

Treatment of acute infectious diarrhea
Intestinal amebiasis and other susceptible enteric protozoal infections in specific markets

Mechanism of Action

Halogenated 8-hydroxyquinoline derivative with luminal antimicrobial and antiprotozoal activity
Exerts local bacteriostatic, fungistatic, and amebicidal effects within the gastrointestinal tract with minimal systemic absorption

Contraindications

Hypersensitivity to broxyquinoline, other hydroxyquinolines, or iodine derivatives
Severe hepatic impairment
Severe renal impairment

Adverse Reactions

Gastrointestinal upset, nausea, abdominal pain
Allergic skin reactions, rash, pruritus
Rare reports of peripheral neuropathy with prolonged or high-dose hydroxyquinoline use

Drug Interactions

May interfere with thyroid function tests due to iodine content
Potential decreased oral bioavailability of concurrent divalent or trivalent cations
Risk of cumulative neurotoxicity with other systemically absorbed hydroxyquinolines (e.g., clioquinol)

Curated Content: Needs Vetting Before Put to Clinical Use